Century Therapeutics, Inc. (IPSC) Reports Q2 Loss, Tops Revenue Estimates

Century Therapeutics, Inc. (IPSC) came out with a quarterly loss of $0.38 per share versus the Zacks Consensus Estimate of a loss of$ 0.50. This compares to loss of $0.56 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 24%. A quarter ago, it was expected that this company would post a loss of$ 0.50 per share when it actually produced a loss of $0.45, delivering a surprise of 10%. Over the last four quarters, the company has s ...